从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均41.83倍，行业中值45.41倍，爱尔眼科排 名第22位。 股东方面，截至2025年3月31日，爱尔眼科股东户数347329户，较上次减少31805户，户均持股市值 35.28万元，户均持股数量2.76万股。 6月10日，爱尔眼科今日收盘12.47元，下跌1.42%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到31.38倍，总市值1162.88亿元。 爱尔眼科医院集团股份有限公司的主营业务是各类眼科疾病诊疗、手术服务与医学验光配镜。公司的主 要产品是屈光项目、白内障项目、眼前段项目、眼后段项目、视光服务项目。 来源：金融界 序号股票简称PE(TTM)PE(静)市净率总市值(元)22爱尔眼科31.3832.705.321162.88亿行业平均 41.8347.923.53160.68亿行业中值45.4150.442.7559.16亿1润达医疗-290.09191.972.50106.12亿2何氏眼 科-149.86-130.411.8735.73亿3*ST生物-146.42-142.3512.0328.25亿4诚达药业-75.35-129. ...

最新一期业绩显示，2025年一季报，公司实现营业收入60.26亿元，同比15.97%；净利润10.50亿元，同 比16.71%，销售毛利率48.02%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)22爱尔眼科31.5832.915.361170.34亿行业平均 40.3546.493.46158.30亿行业中值47.2152.292.7259.39亿1润达医疗-285.64189.022.47104.49亿2何氏眼 科-142.30-123.831.7733.93亿3*ST生物-118.20-114.919.7122.80亿4诚达药业-74.55-127.721.6835.89亿5普 瑞眼科-66.51-59.752.8560.87亿6皓宸医疗-52.44-63.076.2223.77亿7创新医疗-50.98-56.933.0353.48亿8国际 医学-45.16-45.423.23115.42亿9百诚医药-36.42-88.911.8446.89亿10金域医学-35.05-35.891.99136.85亿11睿 智医药-29.77-25.554.7457.86亿 来源：金融界 资金流向方面，6月 ...

Core Viewpoint - Aier Eye Hospital, the largest ophthalmology chain globally, has seen its annual revenue grow from approximately 600 million yuan in 2009 to over 20 billion yuan in 2024, yet its stock price has significantly declined in recent years, raising concerns among investors [1]. Financial Performance - Aier Eye Hospital's revenue for 2024 is projected to be 20.983 billion yuan, with a net profit of 3.556 billion yuan and a net profit excluding non-recurring items of 3.099 billion yuan [7][17]. - The company has experienced a notable slowdown in revenue growth over the past five years, with growth rates of 19.24%, 25.93%, 7.39%, 26.42%, and 3.02% from 2020 to 2024 [11][13]. - The net profit growth rates during the same period were 25.01%, 34.78%, 8.65%, 33.06%, and 5.87%, while the net profit excluding non-recurring items recorded a negative growth of -11.82% in 2024, marking the first negative growth since its listing [11][14]. Stock Performance - Since its peak on July 1, 2021, Aier Eye Hospital's stock price has declined nearly 70% as of May 29, 2025 [2][3]. - The stock price as of May 30, 2025, was 12.41 yuan per share, significantly lower than its initial public offering price of 28 yuan [6][17]. Market Position and Strategy - Aier Eye Hospital operates 352 hospitals and 229 outpatient departments, ranking first among domestic peers [19]. - The company is focusing on a "1+8+N" development strategy, aiming to establish a world-class ophthalmology center and regional centers to drive overall growth [23][24]. Industry Outlook - The ophthalmology industry is expected to remain resilient despite economic uncertainties, driven by increasing demand due to factors such as population aging and rising prevalence of eye diseases [6][24]. - The company believes that the potential market size for ophthalmology is vast, with low penetration rates in various sub-specialties, indicating significant growth opportunities [23][24].

序号股票简称PE(TTM)PE(静)市净率总市值(元)22爱尔眼科31.7833.125.391177.80亿行业平均 39.3945.553.43156.67亿行业中值44.3052.552.7058.27亿1润达医疗-291.91193.172.52106.79亿2何氏眼 科-139.92-121.761.7533.36亿3*ST生物-120.25-116.909.8823.20亿4诚达药业-72.65-124.471.6334.98亿5普 瑞眼科-66.22-59.492.8460.60亿6皓宸医疗-52.07-62.636.1823.60亿7国际医学-45.20-45.453.24115.51亿8创 新医疗-44.42-49.602.6446.60亿9金域医学-35.08-35.921.99136.94亿10百诚医药-33.59-82.011.6943.25亿11 迪安诊断-22.59-25.381.3990.68亿 来源：金融界 爱尔眼科医院集团股份有限公司的主营业务是各类眼科疾病诊疗、手术服务与医学验光配镜。公司的主 要产品是屈光项目、白内障项目、眼前段项目、眼后段项目、视光服务项目。 最新一期业 ...

最新一期业绩显示，2025年一季报，公司实现营业收入2.08亿元，同比4.32%；净利润57.38万元，同比 103.06%，销售毛利率37.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14光正眼科-14.05-12.5019.1321.83亿行业平均 38.6644.623.37152.83亿行业中值43.3251.712.6756.60亿1润达医疗-296.69196.342.56108.54亿2何氏眼 科-138.99-120.951.7333.14亿3*ST生物-119.91-116.579.8523.13亿4诚达药业-71.50-122.491.6134.42亿5普 瑞眼科-66.28-59.552.8460.66亿6皓宸医疗-51.14-61.516.0723.18亿7国际医学-44.93-45.183.22114.83亿8创 新医疗-43.20-48.242.5745.32亿9金域医学-34.69-35.521.97135.41亿10百诚医药-33.08-80.771.6742.60亿11 迪安诊断-22.22-24.961.3689.18亿 来源：金融界 5月27日，光正眼 ...

5月20日，光正眼科今日收盘4.24元，上涨2.17%，最新市净率19.27，创40天以来新低，总市值21.98亿 元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14光正眼科-14.15-12.5919.2721.98亿行业平均 38.4944.343.45153.98亿行业中值39.2651.172.7152.70亿1润达医疗-295.54195.572.55108.11亿2何氏眼 科-141.11-122.801.7633.64亿3*ST生物-124.18-120.7310.2023.96亿4诚达药业-70.53-120.841.5933.96亿5普 瑞眼科-68.23-61.292.9262.44亿6皓宸医疗-51.88-62.406.1623.52亿7国际医学-45.90-46.163.29117.31亿8创 新医疗-45.01-50.262.6847.22亿9金域医学-35.68-36.542.02139.30亿10百诚医药-29.81-72.771.5038.38亿11 迪安诊断-22.78-25.591.4091.43亿 截至2025年一季报，共有3家机构持仓光正眼科，其中其他3家 ...

爱尔眼科医院集团股份有限公司的主营业务是各类眼科疾病诊疗、手术服务与医学验光配镜。公司的主 要产品是屈光项目、白内障项目、眼前段项目、眼后段项目、视光服务项目。 最新一期业绩显示，2025年一季报，公司实现营业收入60.26亿元，同比15.97%；净利润10.50亿元，同 比16.71%，销售毛利率48.02%。 5月15日，爱尔眼科今日收盘12.87元，下跌1.91%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到32.39倍，总市值1200.39亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均37.79倍，行业中值38.85倍，爱尔眼科排 名第25位。 截至2025年一季报，共有107家机构持仓爱尔眼科，其中基金105家、其他2家，合计持股数416294.56万 股，持股市值552.84亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)25爱尔眼科32.3933.765.501200.39亿行业平均 37.7943.763.40151.99亿行业中值38.8551.492.7248.17亿1润达医疗-303.46200.812.62111.01亿2何氏眼 科-136 ...

Core Insights - The company reported a revenue of 20.983 billion yuan in 2024, a year-on-year increase of 3%, and a net profit attributable to shareholders of 3.556 billion yuan, up 6% [1] - In Q1 2025, the company achieved a revenue of 6.026 billion yuan, representing a 16% increase, and a net profit attributable to shareholders of 1.050 billion yuan, up 17% [1] Operational Analysis - The outpatient and surgical volumes showed steady growth, with outpatient visits reaching 16.94 million (up 12%) and surgical procedures totaling 1.29 million (up 9%) in 2024 [2] - Revenue from refractive projects was 7.603 billion yuan (up 36%), cataract projects generated 3.489 billion yuan (up 17%), and vision service projects brought in 5.279 billion yuan (up 25%) [2] - Domestic revenue was 18.070 billion yuan (up 2.94%) with a gross margin of 48.03%, while overseas revenue reached 2.625 billion yuan (up 15.1%), with European revenue at 2.031 billion yuan (up 18.05%) [2] Business Expansion and AI Integration - The company expanded its network by acquiring 87 medical institutions, enhancing its presence in domestic markets, particularly at the county level [3] - By the end of 2024, the company operated 352 hospitals and 229 outpatient departments, benefiting from a tiered chain model for resource sharing [3] - The company launched the AierGPT model and digital assistant "AiKe," serving 2.01 million users, and collaborated with institutions like the Chinese Academy of Sciences to accelerate AI technology in ophthalmology [3] Profit Forecast and Valuation - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 4.137 billion, 4.806 billion, and 5.561 billion yuan, each reflecting a 16% year-on-year growth [4] - The earnings per share (EPS) are projected to be 0.44, 0.52, and 0.60 yuan for the respective years, with corresponding price-to-earnings (PE) ratios of 29, 25, and 21 [4]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 " 使所有人，无论贫穷富裕，都享有眼健康的权利 。"这是爱尔眼科（300015.SZ）在其官方网站首页中央位置展示的宣言，也是公司的核心宗旨和追 求。 作为一家专门从事眼科疾病诊断、治疗、手术以及医学验光配镜服务的连锁医疗机构。 自2009年在深交所上市以来， 爱尔眼科成为首家进入A股市场的 眼科医疗机构 ，在资本市场风光无限，被称为"眼茅"。公司的创始人陈邦也因爱尔眼科的成功多次成为湖南省首富。 在过去的二十多年里，爱尔眼科从长沙起步，逐渐扩展到全国范围， 凭借其强大的融资能力和快速的扩张速度占据国内眼科行业的霸主地位 。2021年7 月1日，爱尔眼科股价创下历史高点的41.98元/股，当日公司总市值3853.05亿元。然而， 公司如今的市值只有不到1300亿元，其独特的商业模式也备受 质疑 。 今天，小编就为大家深入剖析 这家传奇的民营眼科龙头，是否真的繁华落尽 ？ # 业绩增长的压力 从上表中我们也可以发现， 公司的业绩增速有放缓的趋势 ...